1. Sixty dollar experimental vaccine rolled out in east Chinese city  The Phuket News
  2. China rapidly expands use of experimental COVID-19 vaccines  CTV News
  3. Preliminary results find COVID-19 vaccine candidate based on inactivated SARS-CoV-2 virus is safe  Medical Xpress
  4. Eastern Chinese cities to offer ordinary citizens COVID-19 vaccines  Global Times
  5. A Chinese city says it has given some residents a vaccine.  The New York Times
  6. View Full coverage on Google News
WORLD: A US$60 (B1872) double-dose experimental coronavirus vaccine is being made available to some residents in an eastern Chinese city, health officials have said, the first details of a mass rollou

Sixty dollar experimental vaccine rolled out in east Chinese city

China is rapidly increasing the number of people receiving its experimental coronavirus vaccines, with a city offering one to the general public and a biotech company providing another free to students going abroad.China is rapidly increasing the number of people receiving its experimental coronavirus vaccines, with a city offering one to the general public and a biotech company providing another free to students going abroad.

China rapidly expands use of experimental COVID-19 vaccines | CTV News

THE QUEEN could play a key role if a coronavirus vaccine becomes available, according to an expert.THE QUEEN could play a key role if a coronavirus vaccine becomes available, according to an expert.

Queen news: Queen could play key role if coronavirus vaccine becomes available - expert | Royal | News | Express.co.uk

A Chinese COVID-19 vaccine candidate based on the inactivated whole SARS-CoV-2 virus is safe and eli

Preliminary results show Chinese COVID-19 vaccine candidate safe: The Lancet - SHINE News

Treatment is safe and elicits an antibody response, preliminary results have shownTreatment is safe and elicits an antibody response, preliminary results have shown

'Enouraging' Chinese Covid vaccine shows early promise - Wales Online

403 Missing Auth Token

Key workers and those at high risk from COVID-19 would be among the first to receive the jabs in the city of Jiaxing. Others include residents aged between 18 and 59 with 'urgent need for vaccination'.Key workers and those at high risk from COVID-19 would be among the first to receive the jabs in the city of Jiaxing. Others include residents aged between 18 and 59 with 'urgent need for vaccination'.

Coronavirus: Experimental £46 COVID-19 vaccine is made available to residents of Chinese city | Daily Mail Online

Nation’s broken health-care system cannot cope with strain of prolonged pandemicNation’s broken health-care system cannot cope with strain of prolonged pandemic

Report: India selecting 300m people for COVID-19 vaccine | India – Gulf News

MUMBAI: India’s coronavirus infections rose by another 62,212 cases over the previous day and a local media report said on Saturday that the government had begun identifying about 300 million people who would be given the vaccine first when it is ready. The Times of India said that frontline health and sanitation workers, police officials and elderly people with co-morbiditiesMUMBAI: India’s coronavirus infections rose by another 62,212 cases over the previous day and a local media report said on Saturday that the government had begun identifying about 300 million people

India begins selecting people for priority COVID-19 vaccines as over 60,000 more cases recorded | Arab News

Inspections will be carried out at 3 companies that have agreed to supply COVID-19 vaccines to Indonesia - Anadolu AgencyInspections will be carried out at 3 companies that have agreed to supply COVID-19 vaccines to Indonesia - Anadolu Agency

Indonesian team in China to check COVID-19 vaccines

50 African diplomats visited China’s human vaccine research, development, and manufacturing enterprise Sinopharm in the fight against covid-1950 African diplomats visited China’s human vaccine research, development, and manufacturing enterprise Sinopharm in the fight against covid-19

50 African Diplomats on Anti-Covid-19 Visit to China’s Sinopharm | Africanews

Chinese Covid-19 vaccine candidate -- BBIBP-CorV -- that is expected to completely inactivate the SARS-CoV-2 virus, is safe and elicits an antibody response, a study published in The Lancet has found.Chinese Covid-19 vaccine candidate -- BBIBP-CorV -- that is expected to completely inactivate the SARS-CoV-2 virus, is safe and elicits an antibody response, a study published in The Lancet has found.

China's Covid-19 vax is safe, prompts antibody response: Lancet | greatandhra.com

Health authorities in Jiaxing, East China’s Zhejiang Province, announced on Thursday that the city has been administering China’s homegrown inactivated COVID-19 vaccines among high-risk groups and would gradually offer it to ordinary citizens for urgent use.

Eastern Chinese cities to offer ordinary citizens COVID-19 vaccines - Global Times

COVID-19 vaccine, and China-Africa health cooperation, are their focus.

50 African diplomats visit Chinese coronavirus vaccine maker - CGTN

(This October 16 story was refiled to correct spelling of city Jiaxing in 4th paragraph)(This October 16 story was refiled to correct spelling of city Jiaxing in 4th paragraph)

Sinovac coronavirus vaccine offered by Chinese city for emergency use costs $60 | Reuters

NewZimbabwe.com – The Zimbabwe News You Trust is Zimbabwe’s leading online newspaper and published by New Zimbabwe Media Ltd. The platform brings you the latest breaking News, Business, Showbiz, Sports, Diaspora and gives you everything you’ve come to expect and love.Spread This NewsMailOnLine Hopes of getting a Covid-19 vaccine were boosted again today after an experimental Chinese jab was found to be safe and produce an immune response. Every volunteer given a double-dose of state-owned firm Sinopharm’s vaccine made antibodies against SARS-CoV-2, the coronavirus that causes Covid-19. In theory, this would protect them from catching

More Covid-19 vaccine hopes as scientists say experimental Chinese jab is safe - NewZimbabwe.com

Modi also cautioned against any complacency at the decline and called for keeping up the efforts to contain the pandemic.Modi also cautioned against any complacency at the decline and called for keeping up the efforts to contain the pandemic.

Coronavirus vaccine | Focus on cold storage chains, distribution network and monitoring mechanism, says PM - The Hindu

A $60 double-dose experimental coronavirus vaccine is being made available to some residents in an eastern Chinese city, health officials have said, the first details of a mass rollout for an as-yet unproven vaccine. Officials in Jiaxing city said Thursday residents aged between 18 and 59 with "urgent needs" can seek consultations at clinics for a Sinovac Biotech vaccine thatA $60 double-dose experimental coronavirus vaccine is being made available to some residents in an eastern Chinese city, health officials have said, the first details of a mass rollout for an as-yet

$60 experimental coronavirus vaccine rolled out in eastern Chinese city | Deccan Herald

A previous clinical trial reported similar results for a different vaccine that is also based on inactivated whole SARS-CoV-2 virus, but in that study the vaccine was only tested in people aged under 60 years. The latest study, published in The Lancet Infectious Diseases journal, included participants aged between 18 and 80 years, and found that antibody responses were induced in all recipients.A previous clinical trial reported similar results for a different vaccine that is also based on inactivated whole SARS-CoV-2 virus, but in that study the vaccine was only tested in people aged under 60 years. The latest study, published in The Lancet Infectious Diseases journal, included participants aged between 18 and 80 years, and found that antibody responses were induced in all recipients.

Chinese COVID-19 vaccine candidate shows promise in human trial: Study | Health

The Beijing-based Sinovac Biotech’s vaccine — called CoronaVac — is being offered in the city of Jiaxing to care givers, especially epidemic-prevention workers, public service personnel and port inspectors, and will eventually be offered to regular citizens, the state media reported on Friday, quoting officials.The Beijing-based Sinovac Biotech’s vaccine — called CoronaVac — is being offered in the city of Jiaxing to care givers, especially epidemic-prevention workers, public service personnel and port inspectors, and will eventually be offered to regular citizens, the state media reported on Friday, quoting officials.

Sinovac vaccine for Covid offered by Chinese city for emergency use costs $60 - world news - Hindustan Times

Prime Minister Narendra Modi on Saturday reviewed Covid-19 pandemic situation in the country, preparedness of vaccine delivery, distribution & administration. The meeting was attended by Union Health Minister, Principal Secy to PM, Member (Health) NITI Aayog and other Depts of Govt of India.Prime Minister Narendra Modi on Saturday reviewed Covid-19 pandemic situation in the country, preparedness of vaccine delivery, distribution & administration. The meeting was attended by Union Health Minister, Principal Secy to PM, Member (Health) NITI Aayog and other Depts of Govt of India.

PM Modi reviews coronavirus vaccine delivery plan, calls for speedy access to all - Oneindia News

India News: As the world prepares for a vaccine against Covid-19, India has started identifying around 30 crore priority beneficiaries, including high-risk populIndia News: As the world prepares for a vaccine against Covid-19, India has started identifying around 30 crore priority beneficiaries, including high-risk popul

Covid-19: Govt identifying 30 crore who will get vaccine on priority | India News - Times of India

China is positioning itself to be key to any global solution to the pandemic.. Read more at straitstimes.com.East Asia News -China is positioning itself to be key to any global solution to the pandemic.. Read more at straitstimes.com.

Beijing in Covid-19 vaccine race to restore international image, East Asia News & Top Stories - The Straits Times

The group says they have also built the largest cold chain network and distribution system to safely transport and store vaccine

Apollo ready to administer 1 million COVID-19 vaccines a day

On Tuesday, vaccine specialist Vaxart (VXRT) announced it has dosed the first subject in the Phase 1 study of VXA-CoV2-1, the company’s oral, room-temperature stable COVID-19 vaccine candidate.After the vaccine impressed in preclinical models, it is a timely announcement from Vaxart. While the small biotech is significantly behind other, mostly bigger competitors in its Covid-19 vaccine program, as recent events have shown, bringing to market a viable solution is far from hassle free.Earlier this week, Johnson & Johnson halted its Covid-19 vaccine candidate’s Phase 3 study due to a participant’s unexplained illness. That event was swiftly followed by Eli Lily pausing enrollment for its Covid-19 treatment program due to safety concerns.For FBR Riley analyst Mayank Mamtani, the bigger players’ struggles highlight the alternative opportunity Vaxart presents for investors.“As the COVID-19 cases continue to spike WW and leading programs from J&J and AZN experience speedbumps with late-stage development, albeit temporary, it is becoming increasingly important to have multiple shots on goal in the C-19 vaccine landscape and recommend investors diversify positions, including with alternative modalities, e.g., VXRT’s oral candidate, which not only have the potential to be self-administered but are also room-temperature stable and rapidly scalable, conferring significant advantages with respect to stockpiling and distribution, particularly relevant in non-western economies with limited healthcare resources,“ Mamtani commented.Vaxart stock has experienced a roller coaster ride in 2020. Despite being up by 1637% year-to-date, the share price has actually retreated by over 60% since the July yearly highs. Mamtani believes that in addition to the pullback, its “valuation disconnect relative to more advanced C-19 vaccine peers, presents an additional compelling buying opportunity.”To this end, Mamtani rates VXRT a Buy along with a $22 price target. Investors could be pocketing a massive 262% gain, should his thesis play out over the next year. (To watch Mamtani’s track record, click here)Overall, only one other analyst is currently keeping a tab on Vaxart’s progress, also recommending the stock a Buy. Vaxart, therefore, has a Moderate Buy consensus rating backed with a $19.50 average price target. The figure suggests potential upside of 220% in the year ahead. (See VXRT stock analysis on TipRanks)To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analyst. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.On Tuesday, vaccine specialist Vaxart (VXRT) announced it has dosed the first subject in the Phase 1 study of VXA-CoV2-1, the company’s oral, room-temperature stable COVID-19 vaccine candidate.After the vaccine impressed in preclinical models, it is a timely announcement from Vaxart. While the small biotech is significantly behind other, mostly bigger competitors in its Covid-19 vaccine program, as recent events have shown, bringing to market a viable solution is far from hassle free.Earlier this week, Johnson & Johnson halted its Covid-19 vaccine candidate’s Phase 3 study due to a participant’s unexplained illness. That event was swiftly followed by Eli Lily pausing enrollment for its Covid-19 treatment program due to safety concerns.For FBR Riley analyst Mayank Mamtani, the bigger players’ struggles highlight the alternative opportunity Vaxart presents for investors.“As the COVID-19 cases continue to spike WW and leading programs from J&J and AZN experience speedbumps with late-stage development, albeit temporary, it is becoming increasingly important to have multiple shots on goal in the C-19 vaccine landscape and recommend investors diversify positions, including with alternative modalities, e.g., VXRT’s oral candidate, which not only have the potential to be self-administered but are also room-temperature stable and rapidly scalable, conferring significant advantages with respect to stockpiling and distribution, particularly relevant in non-western economies with limited healthcare resources,“ Mamtani commented.Vaxart stock has experienced a roller coaster ride in 2020. Despite being up by 1637% year-to-date, the share price has actually retreated by over 60% since the July yearly highs. Mamtani believes that in addition to the pullback, its “valuation disconnect relative to more advanced C-19 vaccine peers, presents an additional compelling buying opportunity.”To this end, Mamtani rates VXRT a Buy along with a $22 price target. Investors could be pocketing a massive 262% gain, should his thesis play out over the next year. (To watch Mamtani’s track record, click here)Overall, only one other analyst is currently keeping a tab on Vaxart’s progress, also recommending the stock a Buy. Vaxart, therefore, has a Moderate Buy consensus rating backed with a $19.50 average price target. The figure suggests potential upside of 220% in the year ahead. (See VXRT stock analysis on TipRanks)To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analyst. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

Vaxart: An Alternative Opportunity in the COVID-19 Vaccine Landscape

The move is aimed at boosting public confidence in homegrown inoculations, the WSJ reported, citing a company website and some students who applied for it.

China's Sinopharm Offers Experimental COVID-19 Vaccines to Students - The Wire Science

BEIJING, Oct 16 — One of China’s front-running coronavirus vaccine candidates was shown to be safe and triggered immune responses in a combined early and mid-stage test in humans, researchers said. The potential vaccine, dubbed BBIBP-CorV, is being developed by the Beijing Institute of...BEIJING, Oct 16 — One of China’s front-running coronavirus vaccine candidates was shown to be safe and triggered immune responses in a combined early and mid-stage test in humans, researchers said. The potential vaccine, dubbed BBIBP-CorV, is being developed by the Beijing Institute of...

Study: Covid-19 vaccine candidate from China’s CNBG shows promise in human test | Life | Malay Mail

Chinese drug companies have five vaccines in final stages of testing but none is approved for public use. They are part of a global race to develop a vaccine that, if successful, offers the fledgling Chinese industry the potential for prestige and worldwide sales.Chinese drug companies have five vaccines in final stages of testing but none is approved for public use. They are part of a global race to develop a vaccine that, if successful, offers the fledgling Chinese industry the potential for prestige and worldwide sales.

Covid-19: China rapidly expands use of its experimental coronavirus vaccines - World News

North Carolina's Department of Health and Human Services unveiled a plan Friday in which it described the residents it will prioritize when a coronavirus vaccine gets approved.North Carolina's Department of Health and Human Services unveiled a plan Friday in which it described the residents it will prioritize when a coronavirus vaccine gets approved.

North Carolina unveils plan to deploy coronavirus vaccine | State and Regional News | greensboro.com

Participants aged 60 and older were slower to respond, taking 42 days before antibodies were detected in all recipients compared with 28 days for participants aged 18-59Participants aged 60 and older were slower to respond, taking 42 days before antibodies were detected in all recipients compared with 28 days for participants aged 18-59

Preliminary results show Chinese Covid-19 vaccine candidate safe | Dhaka Tribune

Hope for a coronavirus vaccine have been boosted after a Chinese jab proved to be safe and produced an antibody response, scientists have said. The research, published in the journal Lancet Infectious Disease, is based on small early phase randomised clinical trials involving 640 participants. The vaccine candidate is based on inactivated coronavirus. Scientists said thoseHope for a coronavirus vaccine have been boosted after a Chinese jab proved to be safe and produced an antibody response, scientists have said. The research, published in the journal Lancet

Hope for coronavirus vaccine boosted as scientists say Chinese jab safe and produces immune response | London Evening Standard

Serum Institute of India (SII) can manufacture 700-800 million vaccine doses every year. said executive director Dr Suresh Jadhav.Serum Institute of India (SII) can manufacture 700-800 million vaccine doses every year. said executive director Dr Suresh Jadhav.

Oxford COVID-19 vaccine likely to be ready by March 2021: Serum Institute of India

Officials in Jiaxing city said residents with urgent needs can seek vaccination in the first mass roll-out.Officials in Jiaxing city said residents with urgent needs can seek vaccination in the first mass roll-out.

Covid-19: China rolls out $60 experimental vaccine for residents - News | Khaleej Times

BEIJING: A US$60 double-dose experimental COVID-19 vaccine is being made available to some residents in an eastern Chinese city, health officials ...BEIJING: A US$60 double-dose experimental COVID-19 vaccine is being made available to some residents in an eastern Chinese city, health officials ...

US$60 experimental COVID-19 vaccine rolled out in east Chinese city - CNA

China has begun inoculating the general public against the coronavirus with an experimental vaccine that has not yet completed clinical trials.Health officials in Jiaxing, Zhejiang province, said theChina has begun inoculating the general public against the coronavirus with an experimental vaccine that has not yet completed clinical trials.Health officials in Jiaxing, Zhejiang province, said the

Fresh hope of a Covid-19 vaccine has emerged from a new trial showing an experimental Chinese jab is "safe and elicits an antibody response" to fight the virus.Fresh hope of a Covid-19 vaccine has emerged from a new trial showing an experimental Chinese jab is "safe and elicits an antibody response" to fight the virus.

Chinese vaccine trial offers fresh hope in war against pandemic - Independent.ie

A €50 double-dose experimental coronavirus vaccine is being made available to some residents in an eastern Chinese city, health officials have said, the first details of a mass rollout for an as-yet unproven vaccine. Officials in Jiaxing city said that residents aged between 18 and 59 with...A €50 double-dose experimental coronavirus vaccine is being made available to some residents in an eastern Chinese city, health officials have said, the first details of a mass rollout for an as-yet unproven vaccine. Officials in Jiaxing city said that residents aged between 18 and 59 with...

€50 experimental COVID-19 vaccine rolled out in east Chinese city

Clinical trials of the coronavirus vaccine have involved 640 peopleClinical trials of the coronavirus vaccine have involved 640 people

Chinese Covid-19 vaccine candidate safe, early reports say | Metro News

Researchers said those aged 60 and over were slower to respond to the BBIBP-CorV vaccine.Researchers said those aged 60 and over were slower to respond to the BBIBP-CorV vaccine.

Chinese Covid-19 vaccine candidate 'safely triggers antibody response' | ITV News

Currently, scientists, health researchers and drugmakers all over the world are racing to produce a safe and effective vaccine against coronavirus.Currently, scientists, health researchers and drugmakers all over the world are racing to produce a safe and effective vaccine against coronavirus.

This vaccine includes the killed virus mixed with aluminium hydroxide, which is known to boost immune responses.This vaccine includes the killed virus mixed with aluminium hydroxide, which is known to boost immune responses.

China's Covid-19 vaccine candidate is safe and prompts antibody response - early results from study

Data from a Phase 1/2 randomized controlled trial of vaccine candidate, BBIBP-CorV, is shown to be safe.Data from a Phase 1/2 randomized controlled trial of vaccine candidate, BBIBP-CorV, is shown to be safe.

COVID-19 Vaccine Induces Immune Response | Contagion Live

The market leader in flu vaccines is trailing in the race to find an effective coronavirus vaccine.The market leader in flu vaccines is trailing in the race to find an effective coronavirus vaccine.

Sanofi and Translate Bio Have a COVID-19 Vaccine Candidate Ready for Clinical Trials | The Motley Fool